Tekla Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Tekla Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.06M	Hold	423,869	–	–	0.04%	130
2023 Q1	$1.14M	Hold	423,869	–	–	0.04%	136
2022 Q4	$2.3M	Hold	423,869	–	–	0.09%	108
2022 Q3	$5.29M	Hold	423,869	–	–	0.22%	75
2022 Q2	$2.09M	Hold	423,869	–	–	0.08%	110
2022 Q1	$3.22M	Hold	423,869	–	–	0.11%	106
2021 Q4	$4.33M	Sell	423,869 -200,500	-32%	-$2.56M	0.14%	103
2021 Q3	$8.38M	Hold	624,369	–	–	0.27%	80
2021 Q2	$13.7M	Buy	624,369 +232,615	+59%	+$5.17M	0.45%	55
2021 Q1	$9.43M	Buy	+391,754	New	+$9.1M	0.32%	79

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tekla Capital Management's GTHX Position: Q2 2023 in Review

Tekla Capital Management held its G1 Therapeutics, Inc. Common Stock (GTHX) position steady in Q2 2023 at 423,869 shares worth $1.06M. The position accounts for 0.04% of the portfolio, ranked #130.

Tekla Capital Management first reported a position in GTHX in Q1 2021 and has held it in 10 quarters since. The position peaked at $13.7M in Q2 2021. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

Tekla Capital Management held 423,869 shares of G1 Therapeutics, Inc. Common Stock worth $1.06M as of Q2 2023.
Tekla Capital Management left its G1 Therapeutics, Inc. Common Stock share count unchanged in Q2 2023.
G1 Therapeutics, Inc. Common Stock made up 0.04% of Tekla Capital Management's portfolio in Q2 2023, its #130 holding.
Tekla Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 10 quarters since.
Tekla Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $13.7M in Q2 2021.
80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.